In a report released today, Matt Miksic from Barclays maintained a Buy rating on Becton Dickinson (BDX – Research Report), with a price target of $312.00. The company’s shares closed last Friday at $234.68.
Miksic covers the Healthcare sector, focusing on stocks such as Medtronic, Baxter International, and LivaNova. According to TipRanks, Miksic has an average return of 6.9% and a 59.33% success rate on recommended stocks.
In addition to Barclays, Becton Dickinson also received a Buy from Piper Sandler’s Jason Bednar in a report issued on May 3. However, on May 2, TD Cowen maintained a Hold rating on Becton Dickinson (NYSE: BDX).
The company has a one-year high of $284.02 and a one-year low of $228.00. Currently, Becton Dickinson has an average volume of 1.35M.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Becton Dickinson (BDX) Company Description:
Founded in 1897, Becton, Dickinson & Co. is a New Jersey-based medical technology company. The company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional.
